Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 410

1.

Baseline Characteristics of Participants in the ASPREE (Aspirin in Reducing Events in the Elderly) Study.

McNeil JJ, Woods RL, Nelson MR, Murray AM, Reid CM, Kirpach B, Storey E, Shah RC, Wolfe RS, Tonkin AM, Newman AB, Williamson JD, Lockery JE, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Trevaks RE, Orchard SG, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Grimm RH; ASPREE Investigator Group.

J Gerontol A Biol Sci Med Sci. 2019 Jan 22. doi: 10.1093/gerona/gly278. [Epub ahead of print] No abstract available.

2.

Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.

McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM, Lockery JE, Kirpach B, Storey E, Shah RC, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Johnston CI, Ryan J, Radziszewska B, Jelinek M, Malik M, Eaton CB, Brauer D, Cloud G, Wood EM, Mahady SE, Satterfield S, Grimm R, Murray AM; ASPREE Investigator Group.

N Engl J Med. 2018 Oct 18;379(16):1509-1518. doi: 10.1056/NEJMoa1805819. Epub 2018 Sep 16.

3.

Effect of Aspirin on Disability-free Survival in the Healthy Elderly.

McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, Storey E, Shah RC, Lockery JE, Tonkin AM, Newman AB, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Ryan J, Radziszewska B, Grimm R, Murray AM; ASPREE Investigator Group.

N Engl J Med. 2018 Oct 18;379(16):1499-1508. doi: 10.1056/NEJMoa1800722. Epub 2018 Sep 16.

4.

Effect of Aspirin on All-Cause Mortality in the Healthy Elderly.

McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, Kirpach B, Shah RC, Ives DG, Storey E, Ryan J, Tonkin AM, Newman AB, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Radziszewska B, Grimm R, Murray AM; ASPREE Investigator Group.

N Engl J Med. 2018 Oct 18;379(16):1519-1528. doi: 10.1056/NEJMoa1803955. Epub 2018 Sep 16.

5.

Eulogy John Ludbrook: Surgeon, physiologist and biostatistician.

Evans RG, Johnston CI.

Clin Exp Pharmacol Physiol. 2017 Nov;44(11):1075-1076. doi: 10.1111/1440-1681.12843. No abstract available.

PMID:
28802061
6.

The Australian Snakebite Project, 2005-2015 (ASP-20).

Johnston CI, Ryan NM, Page CB, Buckley NA, Brown SG, O'Leary MA, Isbister GK.

Med J Aust. 2017 Aug 7;207(3):119-125.

PMID:
28764620
7.

Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study.

McNeil JJ, Woods RL, Nelson MR, Murray AM, Reid CM, Kirpach B, Storey E, Shah RC, Wolfe RS, Tonkin AM, Newman AB, Williamson JD, Lockery JE, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Trevaks RE, Orchard SG, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Grimm RH; ASPREE Investigator Group.

J Gerontol A Biol Sci Med Sci. 2017 Oct 12;72(11):1586-1593. doi: 10.1093/gerona/glw342. Erratum in: J Gerontol A Biol Sci Med Sci. 2019 Jan 22;:.

8.

Australian taipan (Oxyuranus spp.) envenoming: clinical effects and potential benefits of early antivenom therapy - Australian Snakebite Project (ASP-25).

Johnston CI, Ryan NM, O'Leary MA, Brown SG, Isbister GK.

Clin Toxicol (Phila). 2017 Feb;55(2):115-122. doi: 10.1080/15563650.2016.1250903. Epub 2016 Nov 30.

PMID:
27903075
9.

Comparative sensitivity of commercially available aPTT reagents to mulga snake (Pseudechis australis) venom.

Lincz LF, Scorgie FE, Johnston CI, O'Leary M, Prasad R, Seldon M, Favaloro E, Isbister GK.

Pathology. 2014 Aug;46(5):444-9. doi: 10.1097/PAT.0000000000000120.

PMID:
24977733
10.

Short- and long-term survival in treated elderly hypertensive patients with or without diabetes: findings from the Second Australian National Blood Pressure study.

Chowdhury EK, Owen A, Ademi Z, Krum H, Johnston CI, Wing LM, Nelson MR, Reid CM; Second Australian National Blood Pressure Study Management Committee.

Am J Hypertens. 2014 Feb;27(2):199-206. doi: 10.1093/ajh/hpt212. Epub 2013 Nov 18.

PMID:
24249722
11.

Mulga snake (Pseudechis australis) envenoming: a spectrum of myotoxicity, anticoagulant coagulopathy, haemolysis and the role of early antivenom therapy - Australian Snakebite Project (ASP-19).

Johnston CI, Brown SG, O'Leary MA, Currie BJ, Greenberg R, Taylor M, Barnes C, White J, Isbister GK; ASP investigators.

Clin Toxicol (Phila). 2013 Jun;51(5):417-24. doi: 10.3109/15563650.2013.787535. Epub 2013 Apr 15.

PMID:
23586640
12.

Age-dependent regulation of renal vasopressin V(1A) and V₂ receptors in rats with genetic hypertension: implications for the treatment of hypertension.

Burrell LM, Risvanis J, Dean RG, Patel SK, Velkoska E, Johnston CI.

J Am Soc Hypertens. 2013 Jan-Feb;7(1):3-13. doi: 10.1016/j.jash.2012.11.004. Epub 2012 Dec 14.

PMID:
23246465
13.

Death adder envenoming causes neurotoxicity not reversed by antivenom--Australian Snakebite Project (ASP-16).

Johnston CI, O'Leary MA, Brown SG, Currie BJ, Halkidis L, Whitaker R, Close B, Isbister GK; ASP Investigators.

PLoS Negl Trop Dis. 2012;6(9):e1841. doi: 10.1371/journal.pntd.0001841. Epub 2012 Sep 27.

14.

High-salt diet increases glomerular ACE/ACE2 ratio leading to oxidative stress and kidney damage.

Bernardi S, Toffoli B, Zennaro C, Tikellis C, Monticone S, Losurdo P, Bellini G, Thomas MC, Fallo F, Veglio F, Johnston CI, Fabris B.

Nephrol Dial Transplant. 2012 May;27(5):1793-800. doi: 10.1093/ndt/gfr600. Epub 2011 Oct 29.

PMID:
22036945
15.

Prediction of cell penetrating peptides by support vector machines.

Sanders WS, Johnston CI, Bridges SM, Burgess SC, Willeford KO.

PLoS Comput Biol. 2011 Jul;7(7):e1002101. doi: 10.1371/journal.pcbi.1002101. Epub 2011 Jul 14.

16.

Cholesterol complacency in Australia: time to revisit the basics of cardiovascular disease prevention.

Carrington MJ, Retegan C, Johnston CI, Jennings GL, Stewart S.

J Clin Nurs. 2009 Mar;18(5):678-86. doi: 10.1111/j.1365-2702.2008.02507.x. Epub 2008 Nov 25.

PMID:
19077020
17.

Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study.

Nelson MR, Reid CM, Ames DA, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Krum H, Storey E, Tonkin A, Wolfe R, Woods R, McNeil JJ.

Med J Aust. 2008 Jul 21;189(2):105-9.

PMID:
18637782
18.

Smaller aortic dimensions do not fully account for the greater pulse pressure in elderly female hypertensives.

Dart AM, Kingwell BA, Gatzka CD, Willson K, Liang YL, Berry KL, Wing LM, Reid CM, Ryan P, Beilin LJ, Jennings GL, Johnston CI, McNeil JJ, MacDonald GJ, Morgan TO, West MJ, Cameron JD.

Hypertension. 2008 Apr;51(4):1129-34. doi: 10.1161/HYPERTENSIONAHA.107.106310. Epub 2008 Feb 7.

PMID:
18259023
19.

Similar effects of treatment on central and brachial blood pressures in older hypertensive subjects in the Second Australian National Blood Pressure Trial.

Dart AM, Cameron JD, Gatzka CD, Willson K, Liang YL, Berry KL, Wing LM, Reid CM, Ryan P, Beilin LJ, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Morgan TO, West MJ, Kingwell BA.

Hypertension. 2007 Jun;49(6):1242-7. Epub 2007 Apr 30.

PMID:
17470723
20.

Developmental expression of ACE2 in the SHR kidney: a role in hypertension?

Tikellis C, Cooper ME, Bialkowski K, Johnston CI, Burns WC, Lew RA, Smith AI, Thomas MC.

Kidney Int. 2006 Jul;70(1):34-41. Epub 2006 May 17.

21.

Brachial blood pressure but not carotid arterial waveforms predict cardiovascular events in elderly female hypertensives.

Dart AM, Gatzka CD, Kingwell BA, Willson K, Cameron JD, Liang YL, Berry KL, Wing LM, Reid CM, Ryan P, Beilin LJ, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Morgan TO, West MJ.

Hypertension. 2006 Apr;47(4):785-90. Epub 2006 Feb 27.

PMID:
16505196
22.

Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.

Jandeleit-Dahm K, Lassila M, Davis BJ, Candido R, Johnston CI, Allen TJ, Burrell LM, Cooper ME.

J Hypertens. 2005 Nov;23(11):2071-82.

PMID:
16208151
23.

Who's really hypertensive?--Quality control issues in the assessment of blood pressure for randomized trials.

Reid CM, Ryan P, Miles H, Willson K, Beilin LJ, Brown MA, Jennings GL, Johnston CI, Macdonald GJ, Marley JE, McNeil JJ, Morgan TO, West MJ, Wing LM.

Blood Press. 2005;14(3):133-8.

PMID:
16036492
24.

Pharmacology of irbesartan.

Johnston CI.

Expert Opin Investig Drugs. 1999 May;8(5):655-70.

PMID:
15992121
25.

Predictors of failure to initiate randomized treatment in a large trial of antihypertensive drug therapy in the aged.

Nelson MR, Ryan P, Willson K, Reid CM, Beilin LJ, Jennings GL, Johnston CI, Macdonald GJ, Marley JE, McNeil JJ, Morgan TO, West MJ, Wing LM.

Am J Hypertens. 2005 Jun;18(6):885-8.

PMID:
15925752
26.

Identification of angiotensin converting enzyme 2 in the rodent retina.

Tikellis C, Johnston CI, Forbes JM, Burns WC, Thomas MC, Lew RA, Yarski M, Smith AI, Cooper ME.

Curr Eye Res. 2004 Dec;29(6):419-27.

PMID:
15764086
27.

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes.

Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME.

J Hypertens. 2005 Mar;23(3):463-73. Review.

PMID:
15716683
28.

Myocardial infarction increases ACE2 expression in rat and humans.

Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, Cooper ME, Johnston CI.

Eur Heart J. 2005 Feb;26(4):369-75; discussion 322-4. Epub 2005 Jan 25.

PMID:
15671045
29.

ACE2, a new regulator of the renin-angiotensin system.

Burrell LM, Johnston CI, Tikellis C, Cooper ME.

Trends Endocrinol Metab. 2004 May-Jun;15(4):166-9. Review.

PMID:
15109615
30.

Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy.

Davis BJ, Johnston CI, Burrell LM, Burns WC, Kubota E, Cao Z, Cooper ME, Allen TJ.

Diabetologia. 2003 Jul;46(7):961-71. Epub 2003 Jun 28.

PMID:
12838387
31.

Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat.

Kubota E, Dean RG, Hubner RA, Casley DJ, Johnston CI, Burrell LM.

Clin Sci (Lond). 2003 Sep;105(3):339-45.

PMID:
12741953
32.

Regulation of angiotensin II receptors in the prostate of the transgenic (mRen-2)27 rat: effect of angiotensin-converting enzyme inhibition.

Fabiani ME, Hawkes DJ, Frauman AG, Tikellis C, Johnston CI, Wilkinson-Berka JL.

Int J Biochem Cell Biol. 2003 Jun;35(6):973-83.

PMID:
12676181
33.

Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy.

Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME.

Hypertension. 2003 Mar;41(3):392-7. Epub 2003 Feb 24.

PMID:
12623933
34.

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ; Second Australian National Blood Pressure Study Group.

N Engl J Med. 2003 Feb 13;348(7):583-92.

35.

Angiotensin-converting enzyme inhibition in adult hypertensive rats: a stereological study of renal filtration surface area.

Dunstan HJ, Briscoe TA, Bertram JF, Johnston CI, Black MJ.

Clin Exp Pharmacol Physiol. 2003 Jan-Feb;30(1-2):72-6.

PMID:
12542457
36.

Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition.

Naitoh M, Risvanis J, Balding LC, Johnston CI, Burrell LM.

Cardiovasc Res. 2002 Apr;54(1):51-7.

PMID:
12062361
37.

Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.

Tikkanen I, Tikkanen T, Cao Z, Allen TJ, Davis BJ, Lassila M, Casley D, Johnston CI, Burrell LM, Cooper ME.

J Hypertens. 2002 Apr;20(4):707-14.

PMID:
11910307
38.

Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia.

Dinh DT, Frauman AG, Somers GR, Ohishi M, Zhou J, Casley DJ, Johnston CI, Fabiani ME.

J Pathol. 2002 Feb;196(2):213-9.

PMID:
11793373
39.

Localization of angiotensin-converting enzyme in the human prostate: pathological expression in benign prostatic hyperplasia.

Nassis L, Frauman AG, Ohishi M, Zhuo J, Casley DJ, Johnston CI, Fabiani ME.

J Pathol. 2001 Dec;195(5):571-9.

PMID:
11745693
40.

Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease.

Kubota E, Dean RG, Hubner RA, Balding LC, Johnston CI, Burrell LM.

Curr Hypertens Rep. 2001 Dec;3 Suppl 2:S31-3. Review.

PMID:
11716804
41.

Effect of angiotensin-converting enzyme inhibition on renal filtration surface area in hypertensive rats.

Black MJ, Briscoe TA, Dunstan HJ, Bertram JF, Johnston CI.

Kidney Int. 2001 Nov;60(5):1837-43.

42.

Angiotensin AT(4) receptors in the normal human prostate and benign prostatic hyperplasia.

Dinh DT, Frauman AG, Casley DJ, Johnston CI, Fabiani ME.

Mol Cell Endocrinol. 2001 Nov 26;184(1-2):187-92.

PMID:
11694354
43.
44.

In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat.

Hubner RA, Kubota E, Casley DJ, Johnston CI, Burrell LM.

J Hypertens. 2001 May;19(5):941-6.

PMID:
11393678
45.

Chronic heart failure in Australian general practice. The Cardiac Awareness Survey and Evaluation (CASE) Study.

Krum H, Tonkin AM, Currie R, Djundjek R, Johnston CI.

Med J Aust. 2001 May 7;174(9):439-44.

PMID:
11386587
46.
47.

Angiotensin receptors: distribution, signalling and function.

Dinh DT, Frauman AG, Johnston CI, Fabiani ME.

Clin Sci (Lond). 2001 May;100(5):481-92. Review.

PMID:
11294688
48.

Defining moments in medicine. Internal medicine.

Johnston CI, Cooper ME, Taylor AJ, Shaw JA.

Med J Aust. 2001 Jan 1;174(1):9-11. No abstract available.

PMID:
11219803
49.

Identification, distribution, and expression of angiotensin II receptors in the normal human prostate and benign prostatic hyperplasia.

Dinh DT, Frauman AG, Sourial M, Casley DJ, Johnston CI, Fabiani ME.

Endocrinology. 2001 Mar;142(3):1349-56.

PMID:
11181554
50.

Angiotensin II type 1 receptor blockade: a novel therapeutic concept.

Johnston CI.

Blood Press Suppl. 2000;1:9-13. Review.

PMID:
11059629

Supplemental Content

Loading ...
Support Center